Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biocytogen Pharmaceuticals (Beijing) Co's quarterly construction in progress
increased
from Jun. 2025 (¥ Mil) to Dec. 2025 (¥49 Mil) but then
declined
from Dec. 2025 (¥49 Mil) to Jun. 2026 (¥ Mil).
Biocytogen Pharmaceuticals (Beijing) Co's annual construction in progress
declined
from Dec. 2023 (¥5 Mil) to Dec. 2024 (¥2 Mil) but then
increased
from Dec. 2024 (¥2 Mil) to Dec. 2025 (¥49 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co Construction In Progress Chart
Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Biocytogen Pharmaceuticals (Beijing) Co Construction In Progress Calculation
It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.
What does a Construction In Progress of ¥ Mil mean?
Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) has a Construction In Progress of ¥ Mil as of Jun. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors.
Is Biocytogen Pharmaceuticals (Beijing) Co's Construction In Progress too high?
Biocytogen Pharmaceuticals (Beijing) Co's current Construction In Progress is ¥ Mil. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's Construction In Progress compare to VRTX and REGN?
Biocytogen Pharmaceuticals (Beijing) Co's Construction In Progress of ¥ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. Biocytogen Pharmaceuticals (Beijing) Co's current Construction In Progress is ¥ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥76.48, compared to a current price of ¥134.13 — trading 75.4% above its estimated fair value. The current Construction In Progress is ¥ Mil. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796), the current Construction In Progress is ¥ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) Overvalued in 2026?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued.
The current stock price of ¥134.13 is trading 75.4% above its estimated GF Value™ of ¥76.48.
GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.
Key valuation signals for SHSE:688796:
Construction In Progress: ¥ Mil
GF Value™: ¥76.48 vs. price of ¥134.13 (75.4% above fair value)
No single metric tells the full story. See the SHSE:688796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a China-based biotechnology company that operates two main businesses: biopharmaceutical research and development, and preclinical research services. Its drug pipeline includes antibody therapeutics developed through its proprietary RenMab and related genetically engineered mouse platforms, which produce fully human antibodies for targets such as CD40, CTLA-4, and others in immuno-oncology. The company also provides preclinical models, gene-editing services, and antibody discovery services to pharmaceutical and biotechnology customers worldwide, generating revenue through research service fees, licensing arrangements, and collaboration agreements. Its animal model business supplies genetically modified mice and related products to academic and industry researchers. Biocytogen is headquartered in Beijing, China, and has expanded internationally, including operations in the United States and Europe, serving global pharmaceutical partners across oncology and other therapeutic areas.
53GF Score
Get the complete analysis for SHSE:688796
Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688796 has been successfully added to your 
